Digital Health Innovation in Cardiovascular Diseases is experiencing a surge of interest as evidenced by the recent significant increase in partnerships in 2023 compared to the same quarter in 2022.
Among the ventures with solutions for Clinical Trials, they are leading in clinical evidence with over half of them having an Evidence Signal greater than 40. This is a promising sign for the future of Cardiovascular Disease treatment as it suggests that these ventures are producing effective solutions that are backed by strong clinical evidence.
However, the total venture capital funding for Cardiovascular solutions in Digital Health decreased by 31% from 2021 to 2022, totaling $3.4B in 2022. This could be due to a number of factors such as market conditions or investor sentiment.
Additionally, the exit activity for Cardiovascular ventures was low in 2022 which followed on in the first quarter of 2023. This could indicate that investors are taking a more cautious approach towards Cardiovascular ventures, or that there are simply fewer opportunities for acquisition.
It’s worth noting that from 2020 to 2023, Patient Solutions was one of the top 3 largest clusters for newly incorporated ventures that focused primarily on Cardiovascular Diseases. This suggests that there is a growing focus on patient-centered solutions in this area of healthcare, which could lead to more effective and personalized treatments for patients with Cardiovascular Diseases.
The “Digital Health Innovation in Cardiovascular Diseases” report includes data on the following companies: Withings, LifeSignals, Eko, Huinno, Omada, Viz.ai, US2.AI, Cleerly, Recora, Elfie, AstraZeneca, Novartis, Roche, Johnson & Johnson, Janssen, Viatris, Servier, Sanofi, Medtronic, Abbott, Boston Scientific, Edwards Lifesciences, SOPHiA Genetics, Integrity Healthcare, Jana Care, One Drop, Tempus, Biofourmis, DispatchHealth, BioIntelliSense, Owkin, Athelas, Koneksa Health, Volta Medical, Implicity, HaploX, CureApp, GOQii, Cathworks, Hello Heart, Cardiokol, Caption Health, Biim Ultrasound, NeuTrace, Arterys, Nutrimedy, Profusa, Foxo Technologies, Novant Health, Mayo Clinic, Rohto Pharmaceutical, Augusta University Health, Franciscan Missionaries of Our Lady Health Systems, GE Healthcare, Observe Medical, Anumana, FemTec Health, TytoCare, Ultromics, FiNC Technologies, Gather Health, Examedi, Medical Informatics, Lark Health, Khosla Ventures, General Catalyst, Bpifrance, DCVC, Asset Management Ventures
HealthTech Alpha, a Galen Growth proprietary solution, powers this report!
Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.
Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.
Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com
© Galen Growth 2023